Foralumab
Based on 1 Customer Validation
Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 98.93%
- CAS No.: 946415-64-1
- Masse moléculaire:145 kDa
-
Stockage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
IC50 & Target
CD3E
In Vivo
Foralumab (0.6-250 μg; p.o. and i.h.; daily, for 5 d) prevents skin xenograft rejection in mice with human immune systems[1].
Foralumab (1-15 μg; p.o.; daily, for 5 d) has good bioavailability of intragastric in humanized mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Humanized NOD/SCID IL-2γc−/− mice with Skin grafts (Humanized mice: CD34+ cells are injected intra-hepatically into irradiated (0.9 Gy) NSG pups within 48 hours of birth) [1]
-
Dosage:15 μg
-
Administration:Oral administration; daily, for 5 days and weekly dosing
-
Result:Showed robust protection against graft rejection and prolongs graft survival.
Reduced proliferation of CD8+ T cells and reduced release of TNF.
Increased the concentration of IL-10.
-
Animal Model:Humanized NOD/SCID IL-2γc−/− mice with Skin grafts (Humanized mice: CD34+ cells are injected intra-hepatically into irradiated (0.9 Gy) NSG pups within 48 hours of birth) [1]
-
Dosage:1, 5, 15, 50, and 250 μg (p.o.), 0.6 mg/kg (i.h.)
-
Administration:Oral administration and subcutaneous injection; daily, for 5 days and weekly dosing
-
Result:Had tolerant to autologous skin grafts in humanized mice.
-
Animal Model:Humanized NOD/SCID IL-2γc−/− mice with Skin grafts (Humanized mice: CD34+ cells are injected intra-hepatically into irradiated (0.9 Gy) NSG pups within 48 hours of birth) [1]
-
Dosage:0, 5, 10, and 15 μg
-
Administration:Oral administration and subcutaneous injection; daily, for 5 days and weekly dosing
-
Result:Increased human Ig on the surface of CD4+ and CD8+ T cells.
Had free mAb in the serum of mice
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow cytometric analysis of 106 Jurkat cells with Foralumab (HY-P99199, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor® 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Product Details
-
CAS No. 946415-64-1
-
Accession P07766
-
Synonyms NI-0401
-
Masse moléculaire 145 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG1 kappa
-
Recommend Isotype Controls
-
Format
-
Human IgG1 kappa
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Pureté
98.93%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Livraison
Shipping with dry ice.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)